- Coordinator
- Fundacio Institut De Bioenginyeria De Catalunya, Spain
- Runs
- 1 October 2023 to 31 March 2025
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101123468
What the project is doing
In the project's own words, from its summary on CORDIS.
Our proposal is to create new nanomedicines for identifying anti-inflammatory therapies. Through the optimisation of synthetic procedures, we aim to control the primary sequence of the polymer, the size of the nanomedicine, and degradation profiles. High-content in vitro screening will be utilised to determine which formulations can most selectively target macrophages and have the strongest anti-inflammatory effect. To test the effectiveness of these formulations, we will collaborate with specialised research groups to conduct appropriate in vivo testing using various models of inflammation.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fundacio Institut De Bioenginyeria De Catalunya | Barcelona | Spain | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI